Gelnique - (10% Gel; Transdermal)

Generic Name	Oxybutynin chloride	Innovator	Allergan
Dosage	10% Gel; Transdermal	Branded US Sales	Less Than $1000 mn
Probable FTF	Less Than 5	Known Para IV Filers	Less Than 5
Other ANDA developers	None	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	Indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*** ******	*** \ ***	***** *, ****	*******	******** ************	****** **** ********

Chronology Of Events